ACN_7.2_Full_Issue_digital

INSIDE
Ari Giagounidis Unwraps Doctor- Patient Gift-Giving Traditions
Can Patients With aHUS Safely Discontinue Eculizumab ?
Patients With Hematologic Malignancies Are Highly Vulnerable to COVID-19
Is Measurable Residual Disease a Valid Biomarker in Myeloma ?

Your source for worldwide news and perspectives on hematology / oncology vol 07 | no 02 January 2021 annual meeting edition www . ASHClinicalNews . org

INSIDE

EDITOR ’ S CORNER

Ari Giagounidis Unwraps Doctor- Patient Gift-Giving Traditions

WRITTEN IN BLOOD

Can Patients With aHUS Safely Discontinue Eculizumab ?

BIG IDEAS in Hematology

Revolutionary data and practice-changing research from the first-ever virtual ASH Annual Meeting
ON LOCATION

Evaluating High-Dose Methotrexate for CNS Relapse in High-Risk DLBCL

BLOOD ADVANCES IN A DIFFERENT VEIN

Patients With Hematologic Malignancies Are Highly Vulnerable to COVID-19

BLOOD ADVANCES IN A DIFFERENT VEIN

Is Measurable Residual Disease a Valid Biomarker in Myeloma ?

PLUS

SPECIAL SYMPOSIUM ON QUALITY

Trainees Propose System- Wide Solutions to Burnout